Condition: Renal carcinoma
rs121913243 in
MET gene and
Renal carcinoma
PMID 25157968 2014 Prospective enterprise-level molecular genotyping of a cohort of cancer patients.
PMID 23213094 2013 Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma.
PMID 18829470 2008 Single-agent and combination therapeutic strategies to inhibit hepatocyte growth factorMET signaling in cancer.
PMID 23610116 2013 Initial clinical sensitivity and acquired resistance to MET inhibition in MET-mutated papillary renal cell carcinoma.
PMID 11750879 2002 Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition.
rs1057519777 in
MTOR gene and
Renal carcinoma
PMID 24631838 2014 A diverse array of cancer-associated MTOR mutations are hyperactivating and can predict rapamycin sensitivity.
PMID 24622468 2014 Tumor genetic analyses of patients with metastatic renal cell carcinoma and extended benefit from mTOR inhibitor therapy.